Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 29, 2015 8:39 PM ET


Company Overview of NephroGenex, Inc.

Executive Profile

Pierre Legault CA, MBA, CPA

Chief Executive Officer, President and Director, NephroGenex, Inc.
AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 9 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Pierre Legault, CA, MBA, CPA, has been the Chief Executive Officer of NephroGenex, Inc. since joining in October 2013 and has been its President since September 1, 2015. Mr. Legault served as the Chief Financial Officer, Executive Vice President and Treasurer of OSI Pharmaceuticals Inc. since December 29, 2008 until January 2011 and served as its Principal Accounting Officer. He served as Chief Executive Officer of Prosidion, Ltd., a mid-size U.K. biotechnology firm. ...

Corporate Headquarters

3200 Beechleaf Court
Raleigh, North Carolina 27604

United States

Phone: 609-986-1780
Fax: --

Board Members Memberships

Independent Director, Member of Audit Committee, Member of Compliance Committee and Member of Independent Committee
Chief Executive Officer, President and Director
Independent Director and Chairman of Audit Committee


Unknown/Other Education
Harvard Business School
McGill University
Bachelor's Degree
Ecole des Hautes Etudes Commerciales de Montreal

Other Affiliations

Annual Compensation

Total Annual Compensation$804,090

Stocks Options

Restricted Stock Awards$30,395
All Other Compensation$40,935
Exercisable Options$114,756
Unexercisable Options$277,768
Total Number of Options$392,524

Total Compensation

Total Annual Cash Compensation$845,025
Total Short Term Compensation$804,090
Other Long Term Compensation$71,330
Total Calculated Compensation$2,807,741

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NephroGenex, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at